![slide deck - Monogram Biosciences](http://s1.studyres.com/store/data/000102464_1-bc6843f3ffa10d09a2f46b6233eb2d3a-300x300.png)
slide deck - Monogram Biosciences
... • Application: Support clinical development of antibody mediated T-cell therapies that induce killing of HIV infected cells • Status: In preliminary discussions to develop standardized, highthroughput methods to measure T-cell killing of HIV infected cells. • Client Support: Primary testing opportun ...
... • Application: Support clinical development of antibody mediated T-cell therapies that induce killing of HIV infected cells • Status: In preliminary discussions to develop standardized, highthroughput methods to measure T-cell killing of HIV infected cells. • Client Support: Primary testing opportun ...
Unconventional T Cell Pleiotropy T Cells
... Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00 www.jimmunol.org ...
... Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00 www.jimmunol.org ...
2016 Detailed Program
... 828: Induction of stem cell-like memory T cells by 1107: Type I interferon signalling supresses influenza virus vaccine is safe and cancer vaccine correlates to enhanced antitumor anti-parasitic CD4+ T cell responses during efficacious in a neonate nonhuman primate ...
... 828: Induction of stem cell-like memory T cells by 1107: Type I interferon signalling supresses influenza virus vaccine is safe and cancer vaccine correlates to enhanced antitumor anti-parasitic CD4+ T cell responses during efficacious in a neonate nonhuman primate ...
2015 Immunology Whitebook - Dalhousie Medical School
... cells and T cells because they have specific receptors on their surface. Antigens are not restricted to infectious agents. Tumors often contain modified proteins or proteins not normally expressed which are seen by the immune system as antigens. In autoimmune disease the immune system recognizes nor ...
... cells and T cells because they have specific receptors on their surface. Antigens are not restricted to infectious agents. Tumors often contain modified proteins or proteins not normally expressed which are seen by the immune system as antigens. In autoimmune disease the immune system recognizes nor ...
Poster Abstracts - Midwinter Conference of Immunologists
... accompanied by tumors that have managed to evade the immune system to continue development. Surprisingly, it has been shown that macrophages account for up to 50% of the tumor mass. Macrophages are heavily influenced by signals released by cells in the surrounding microenvironment. These signals inc ...
... accompanied by tumors that have managed to evade the immune system to continue development. Surprisingly, it has been shown that macrophages account for up to 50% of the tumor mass. Macrophages are heavily influenced by signals released by cells in the surrounding microenvironment. These signals inc ...
RAG mediated rearranging of antigen receptors
... no αβTCR and MHC outside of jawed vertebrates therefore it is difficult to answer what was first rearranging αβTCR Igs and BCR arose before TCR and MHC ...
... no αβTCR and MHC outside of jawed vertebrates therefore it is difficult to answer what was first rearranging αβTCR Igs and BCR arose before TCR and MHC ...
A functional DC cross talk promotes human ILC homeostasis in
... immune cell types has not yet been achieved in these models.3 Much progress has been made to improve overall human lymphoid and myeloid cell engraftment, and to enhance the development of HLArestricted T- and B-cell responses. In contrast, the in vivo development of human innate lymphoid effectors, ...
... immune cell types has not yet been achieved in these models.3 Much progress has been made to improve overall human lymphoid and myeloid cell engraftment, and to enhance the development of HLArestricted T- and B-cell responses. In contrast, the in vivo development of human innate lymphoid effectors, ...
PDF
... immune evasion gene encodes for a 60 amino acid protein that disrupts TAP function by preventing both peptide- and ATPbinding to this complex. Consequently, cells expressing BNLF2a in vitro show decreased surface HLA-class I levels and are refractory to CD8+ T cell killing when co-expressed with tar ...
... immune evasion gene encodes for a 60 amino acid protein that disrupts TAP function by preventing both peptide- and ATPbinding to this complex. Consequently, cells expressing BNLF2a in vitro show decreased surface HLA-class I levels and are refractory to CD8+ T cell killing when co-expressed with tar ...
Effects of intracellular and extracellular heat shock proteins on anti
... of the mammalian innate immune system include the ability (a) to rapidly recognize pathogen and/or tissue injury and (b) to signal the presence of danger to cells to the adaptive immune response (Matzinger 1994). The innate immune system is the very first inflammatory reaction and includes phagocyti ...
... of the mammalian innate immune system include the ability (a) to rapidly recognize pathogen and/or tissue injury and (b) to signal the presence of danger to cells to the adaptive immune response (Matzinger 1994). The innate immune system is the very first inflammatory reaction and includes phagocyti ...
ICI 2016 SUNDAY 21 August 2016
... 828: Induction of stem cell-like memory T cells by 1107: Type I interferon signalling supresses influenza virus vaccine is safe and cancer vaccine correlates to enhanced antitumor anti-parasitic CD4+ T cell responses during efficacious in a neonate nonhuman primate ...
... 828: Induction of stem cell-like memory T cells by 1107: Type I interferon signalling supresses influenza virus vaccine is safe and cancer vaccine correlates to enhanced antitumor anti-parasitic CD4+ T cell responses during efficacious in a neonate nonhuman primate ...
0 - Genetics
... unknown type of antibody. If the reagents contained primarily one antibody specificity it should be possible to absorb the reagents completely with cells of birds possessing only M2, or in the case of anti-Q4 with cells of birds possessing only Q4. Similar absorptions were carried out with reagents ...
... unknown type of antibody. If the reagents contained primarily one antibody specificity it should be possible to absorb the reagents completely with cells of birds possessing only M2, or in the case of anti-Q4 with cells of birds possessing only Q4. Similar absorptions were carried out with reagents ...
Abstract
... Background In patients with primary Sjögren’s syndrome (pSS) local T cell-driven inflammation can contribute to destruction of exocrine glands associated with clinical symptoms of dryness. Evidence is accumulating that IL-7 contributes to inflammation in several autoimmune diseases. Increased levels ...
... Background In patients with primary Sjögren’s syndrome (pSS) local T cell-driven inflammation can contribute to destruction of exocrine glands associated with clinical symptoms of dryness. Evidence is accumulating that IL-7 contributes to inflammation in several autoimmune diseases. Increased levels ...
Bio-Garlic - Pharma Nord
... Bio-Garlic consists of tablets with highly concentrated, garlic. One tablet contains 300 mg of dried garlic powder, standardized for content of the amino acid aliin. Bio-Garlic is produced in a way that preserves the active ingredients and their enzyme activity from the fresh garlic. ...
... Bio-Garlic consists of tablets with highly concentrated, garlic. One tablet contains 300 mg of dried garlic powder, standardized for content of the amino acid aliin. Bio-Garlic is produced in a way that preserves the active ingredients and their enzyme activity from the fresh garlic. ...
Complement-induced regulatory T cells suppress T
... Purified human blood monocytes were cultured in GM-CSF/IL-4–containing media for 72 hours. The generated DC precursors were incubated for 24 hours with supernatants derived from either CD3-, CD3/CD28-, or CD3/CD46-activated T cells (Tr1) or maintained in GM-CSF/IL-4–containing control media. Maturat ...
... Purified human blood monocytes were cultured in GM-CSF/IL-4–containing media for 72 hours. The generated DC precursors were incubated for 24 hours with supernatants derived from either CD3-, CD3/CD28-, or CD3/CD46-activated T cells (Tr1) or maintained in GM-CSF/IL-4–containing control media. Maturat ...
Meningeal Mast Cell Show No Sex differences in EAE
... One disease that shows this prominent sex disparity is multiple sclerosis (MS). → Multiple sclerosis has several subtypes of disease that vary in severity and are driven by different immune responses. As a result, the cellular mechanisms that drive these different responses are of great interest in ...
... One disease that shows this prominent sex disparity is multiple sclerosis (MS). → Multiple sclerosis has several subtypes of disease that vary in severity and are driven by different immune responses. As a result, the cellular mechanisms that drive these different responses are of great interest in ...
ABATEMENT OF TYPE 1 DIABETES AS A RESULT OF
... (compounds which are foreign to the organismal body), with receptor locations found primarily in the liver and kidney (though small amounts of receptors have been identified in the human brain and murine gastrointestinal tract) (Timsit and Negishi, 2007). The main mechanism of action for this pathwa ...
... (compounds which are foreign to the organismal body), with receptor locations found primarily in the liver and kidney (though small amounts of receptors have been identified in the human brain and murine gastrointestinal tract) (Timsit and Negishi, 2007). The main mechanism of action for this pathwa ...
Adaptive immune system
... provide an immediate, but non-specific response. • If pathogens successfully evade the innate response, a third layer of protection will take an action, which is the adaptive immune system. • The adaptive immune system will adapt its response during an infection to improve its recognition of the pat ...
... provide an immediate, but non-specific response. • If pathogens successfully evade the innate response, a third layer of protection will take an action, which is the adaptive immune system. • The adaptive immune system will adapt its response during an infection to improve its recognition of the pat ...
Peer-reviewed Article PDF
... Traditional AIT is performed by subcutaneous injection (SCIT). As an alternative, sublingual immunotherapy (SLIT) has gained some traction because of an apparent reduction in adverse effects [3,4]. AIT has been reported to prevent sensitization for various allergens [4,5]. Nevertheless, AIT has not ...
... Traditional AIT is performed by subcutaneous injection (SCIT). As an alternative, sublingual immunotherapy (SLIT) has gained some traction because of an apparent reduction in adverse effects [3,4]. AIT has been reported to prevent sensitization for various allergens [4,5]. Nevertheless, AIT has not ...
(MHC) molecules
... : short peptide fragments (extracellular origin)-MHC class II complex : Peptide-MHC complexes serve as ligands for TCRs ...
... : short peptide fragments (extracellular origin)-MHC class II complex : Peptide-MHC complexes serve as ligands for TCRs ...
Monoclonal Antibodies Binding Renal Renin
... that recognize not only the catalytic site of renin but also other epitopes that are remote from this site. Intact antibodies, being bivalent, precipitate renin and thus take it out of solution, regardless of whether the catalytic site or another part of the molecule is bound. On the other hand, Fab ...
... that recognize not only the catalytic site of renin but also other epitopes that are remote from this site. Intact antibodies, being bivalent, precipitate renin and thus take it out of solution, regardless of whether the catalytic site or another part of the molecule is bound. On the other hand, Fab ...
The Innate Immune Response in the Pathogenesis of Infectious
... FAPEMIG — Minas Gerais State Agency for Research Development. Part of the Keystone Symposia Global Health Series, travel awards supported by the Bill & Melinda Gates Foundation. Global Health Travel Award Deadline: December 11, 2012 / Abstract & Scholarship Deadline: January 7, 2013 / Late-Breaking ...
... FAPEMIG — Minas Gerais State Agency for Research Development. Part of the Keystone Symposia Global Health Series, travel awards supported by the Bill & Melinda Gates Foundation. Global Health Travel Award Deadline: December 11, 2012 / Abstract & Scholarship Deadline: January 7, 2013 / Late-Breaking ...
Vaccine and Vaccination in farm Animals - DWZ
... A. Natural Passive immunity through colostrum: Calf by the third trimester can recognize some ...
... A. Natural Passive immunity through colostrum: Calf by the third trimester can recognize some ...
Cancer immunotherapy
![](https://commons.wikimedia.org/wiki/Special:FilePath/Peptide_bound_to_Rituximab_FAB.png?width=300)
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.